Ignite enables rapid benchtop scale development of nanoparticle based RNA, DNA, CRISPR, small molecule and protein therapeutics.

Precision NanoSystems (PNI) a global leader of innovative solutions for the discovery, development, and manufacture of nanomedicine based gene and cell therapies, small molecule and protein based drugs is pleased to introduce our newest member of the Nanoassemblr® Platform: the IgniteTM available October 15, 2019. 

"The Ignite embodies everything that made the NanoAssemblr family of instruments the go-to platform for developing new Precision and Gene Therapy medicines for over 100 biopharma companies and featured in over 150 publications." said James Taylor, CEO & Co-Founder PNI. " The Ignite brings our latest innovations developed for clinical manufacturing to the bench, and paves the way for new nanomedicine approaches to treat cancer, rare disease and infectious disease." 

 Optimized drug products are predictably scaled to advanced preclinical and clinical scale with the NxGen technology on the NanoAssemblr BlazeTM and GMP Systems. 

"As the leading provider of RNA/DNA drug manufacturing, we designed Ignite with the end in mind developing a robust, scalable process from the earliest stage. Enabling researchers to create transformative medicines at the bench scale," said Euan Ramsay, CCO & Co-Founder PNI.

PNI’s proprietary NxGenTM scalable continuous-flow microfluidic technology is at the heart of the NanoAssemblr family, using controlled mixing to reproducibly manufacture the highest quality drug products through a single mixer across scales.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.